Rocket Pharmaceuticals received FDA approval for Kresladi, a gene therapy developed to treat leukocyte-adhesion deficiency type 1, an inherited immunodeficiency that can become fatal to infants and young children. Kresladi is the first gene therapy for this ultra-rare disease and the first commercial product for Rocket.
The post FDA Approval Makes Rocket Pharma Gene Therapy the First for Ultra-Rare Immune Disorder appeared first on MedCity News.
